These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Combining selectivity and affinity predictions using an integrated Support Vector Machine (SVM) approach: An alternative tool to discriminate between the human adenosine A(2A) and A(3) receptor pyrazolo-triazolo-pyrimidine antagonists binding sites. Michielan L; Bolcato C; Federico S; Cacciari B; Bacilieri M; Klotz KN; Kachler S; Pastorin G; Cardin R; Sperduti A; Spalluto G; Moro S Bioorg Med Chem; 2009 Jul; 17(14):5259-74. PubMed ID: 19501513 [TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of (4E)-4-(4-substitutedbenzylideneamino)-3-substituted-2,3-dihydro-2-thioxothiazole-5-carbonitrile as novel A2A receptor antagonists. Mishra CB; Sharma D; Prakash A; Kumari N; Kumar N; Luthra PM Bioorg Med Chem; 2013 Oct; 21(19):6077-83. PubMed ID: 23953686 [TBL] [Abstract][Full Text] [Related]
7. Novel bicyclic piperazine derivatives of triazolotriazine and triazolopyrimidines as highly potent and selective adenosine A2A receptor antagonists. Peng H; Kumaravel G; Yao G; Sha L; Wang J; Van Vlijmen H; Bohnert T; Huang C; Vu CB; Ensinger CL; Chang H; Engber TM; Whalley ET; Petter RC J Med Chem; 2004 Dec; 47(25):6218-29. PubMed ID: 15566292 [TBL] [Abstract][Full Text] [Related]
9. Antagonists of the human adenosine A2A receptor. Part 1: Discovery and synthesis of thieno[3,2-d]pyrimidine-4-methanone derivatives. Gillespie RJ; Adams DR; Bebbington D; Benwell K; Cliffe IA; Dawson CE; Dourish CT; Fletcher A; Gaur S; Giles PR; Jordan AM; Knight AR; Knutsen LJ; Lawrence A; Lerpiniere J; Misra A; Porter RH; Pratt RM; Shepherd R; Upton R; Ward SE; Weiss SM; Williamson DS Bioorg Med Chem Lett; 2008 May; 18(9):2916-9. PubMed ID: 18406614 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological activity of new potential agonists for the human adenosine A2A receptor. Bosch MP; Campos F; Niubó I; Rosell G; Díaz JL; Brea J; Loza MI; Guerrero A J Med Chem; 2004 Jul; 47(16):4041-53. PubMed ID: 15267242 [TBL] [Abstract][Full Text] [Related]
11. Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives. Gillespie RJ; Cliffe IA; Dawson CE; Dourish CT; Gaur S; Giles PR; Jordan AM; Knight AR; Lawrence A; Lerpiniere J; Misra A; Pratt RM; Todd RS; Upton R; Weiss SM; Williamson DS Bioorg Med Chem Lett; 2008 May; 18(9):2920-3. PubMed ID: 18407496 [TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists. Baraldi PG; Tabrizi MA; Preti D; Bovero A; Romagnoli R; Fruttarolo F; Zaid NA; Moorman AR; Varani K; Gessi S; Merighi S; Borea PA J Med Chem; 2004 Mar; 47(6):1434-47. PubMed ID: 14998332 [TBL] [Abstract][Full Text] [Related]
13. 2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a new scaffold to obtain potent and selective human A3 adenosine receptor antagonists: new insights into the receptor-antagonist recognition. Lenzi O; Colotta V; Catarzi D; Varano F; Poli D; Filacchioni G; Varani K; Vincenzi F; Borea PA; Paoletta S; Morizzo E; Moro S J Med Chem; 2009 Dec; 52(23):7640-52. PubMed ID: 19743865 [TBL] [Abstract][Full Text] [Related]
14. Antagonists of the human A(2A) adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines. Gillespie RJ; Bamford SJ; Botting R; Comer M; Denny S; Gaur S; Griffin M; Jordan AM; Knight AR; Lerpiniere J; Leonardi S; Lightowler S; McAteer S; Merrett A; Misra A; Padfield A; Reece M; Saadi M; Selwood DL; Stratton GC; Surry D; Todd R; Tong X; Ruston V; Upton R; Weiss SM J Med Chem; 2009 Jan; 52(1):33-47. PubMed ID: 19072055 [TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and biological evaluation of a second generation of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as potent and selective A2A adenosine receptor antagonists. Baraldi PG; Cacciari B; Spalluto G; Bergonzoni M; Dionisotti S; Ongini E; Varani K; Borea PA J Med Chem; 1998 Jun; 41(12):2126-33. PubMed ID: 9622554 [TBL] [Abstract][Full Text] [Related]
16. Antagonists of the human A(2A) receptor. Part 6: Further optimization of pyrimidine-4-carboxamides. Gillespie RJ; Bamford SJ; Clay A; Gaur S; Haymes T; Jackson PS; Jordan AM; Klenke B; Leonardi S; Liu J; Mansell HL; Ng S; Saadi M; Simmonite H; Stratton GC; Todd RS; Williamson DS; Yule IA Bioorg Med Chem; 2009 Sep; 17(18):6590-605. PubMed ID: 19695884 [TBL] [Abstract][Full Text] [Related]
17. Adenosine A2A receptor antagonists: new 8-substituted 9-ethyladenines as tools for in vivo rat models of Parkinson's disease. Volpini R; Dal Ben D; Lambertucci C; Marucci G; Mishra RC; Ramadori AT; Klotz KN; Trincavelli ML; Martini C; Cristalli G ChemMedChem; 2009 Jun; 4(6):1010-9. PubMed ID: 19343763 [TBL] [Abstract][Full Text] [Related]
18. Derivatives of 4-amino-6-hydroxy-2-mercaptopyrimidine as novel, potent, and selective A3 adenosine receptor antagonists. Cosimelli B; Greco G; Ehlardo M; Novellino E; Da Settimo F; Taliani S; La Motta C; Bellandi M; Tuccinardi T; Martinelli A; Ciampi O; Trincavelli ML; Martini C J Med Chem; 2008 Mar; 51(6):1764-70. PubMed ID: 18269230 [TBL] [Abstract][Full Text] [Related]
19. Chiral pyrrolo[2,3-d]pyrimidine and pyrimido[4,5-b]indole derivatives: structure-activity relationships of potent, highly stereoselective A1-adenosine receptor antagonists. Müller CE; Geis U; Grahner B; Lanzner W; Eger K J Med Chem; 1996 Jun; 39(13):2482-91. PubMed ID: 8691445 [TBL] [Abstract][Full Text] [Related]
20. Synthesis and SAR studies of trisubstituted purinones as potent and selective adenosine A2A receptor antagonists. Shao Y; Cole AG; Brescia MR; Qin LY; Duo J; Stauffer TM; Rokosz LL; McGuinness BF; Henderson I Bioorg Med Chem Lett; 2009 Mar; 19(5):1399-402. PubMed ID: 19181527 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]